{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* The dissociation constants (Kd) between the antibodies and RNAse - influenza A M2e antigen conjugate was found to be in the low picomolar range.\n* In one aspect, the invention relates to a monoclonal antibody, preferably to an isolated monoclonal antibody, wherein said monoclonal antibody is specifically binding influenza M2e antigen, and wherein said monoclonal antibody is a human monoclonal antibody, preferably a fully human monoclonal antibody, wherein preferably the EC50 value and/or the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is at most 1000 nM, preferably at most 100 nM, more preferably at most 10 nM, still more preferably at most 1 nM, still more preferably at most 100 pM, still more preferably at most 10 pM, and most preferably at most 1 pM."}
{"final_json": [{"molecule_name": "influenza A M2e antigen conjugate", "protein_target_name": "RNAse", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<10 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<1 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<1 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<1000 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<1000 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<100 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<100 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<10 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<10 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<1 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<1 nM", "unit": "nM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<100 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<100 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<10 pM", "unit": "pM"}, {"molecule_name": "influenza M2e antigen", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<10 pM", "unit": "pM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nLower values of Kd indicate a more specific binding of the antibody to the antigen than higher values. In the context of the application, an antibody is considered to be \"specifically binding an antigen\", when the dissociation constant (Kd) as determined by Friguet ELISA as described above is at most 10 nM (&lt;= 10^\"8 M), preferably at most 1 nM (&lt;= 10^\"9 M), more preferably at most 100 pM (&lt;= 10^\"10 M), still more preferably at most 10 pM \n(&lt;= 10^\"11 M), most preferably at most 1 pM (&lt;= 10^~12 M).\nIn the context of the application, an antibody is further considered to be \"specifically binding an antigen\", when the EC50, preferably determined as described above is at most 1000 nM (&lt;= 10^\"6 M), preferably at most 100 nM (&lt;= 10^\"7 M), more preferably at most 10 nM (&lt;= 10^\"8 M), still more preferably at most 1 nM (&lt;= 10^\"9 M), still more preferably at most 100 pM (&lt;= 10^\"10 M), still more preferably at most 10 pM (&lt;= 10^\"11 M), and most preferably at most 1 pM (&lt;= 10^\"12 M).\nVery preferred are antibodies capable of binding an antigen with a Kd of less than 20 pM, wherein further preferably said Kd is determined in solution.\nVery preferred are antibodies capable of binding an antigen with a EC50 of less than 100 pM, wherein further preferably said EC50 is determined with immobilized antigen."}
{"final_json": [{"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<= 10", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<= 1", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<= 100", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<= 10", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<= 1", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 1000", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 100", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 10", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 1", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 100", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 10", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<= 1", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "< 20", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "antigen", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "< 100", "unit": "pM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\n[0088] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the EC50 value and/or the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is at most 1000 nM (&lt;= 10<sup>\"6</sup> M), preferably at most 100 nM (&lt;= 10<sup>\"7</sup> M), more preferably at most 10 nM (&lt;= 10<sup>\"8</sup> M), still more preferably at most 1 nM (&lt;= 10<sup>\"9</sup> M), still more preferably at most 100 pM (&lt;= 10<sup>\"10</sup> M), still more preferably at most 10 pM (&lt;= 10<sup>\"11</sup> M), and most preferably at most 1 pM (&lt;= 10<sup>\"12</sup> M), wherein preferably said influenza M2e antigen is the extracellular domain of influenza A M2 protein, wherein preferably said influenza M2e antigen is the peptide of any one of SEQ ID NOs 48 to 83, more preferably of any one of SEQ ID NOs 48 to 50, and most preferably of SEQ ID NO:48, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11 , and/or wherein said EC50 value is determined by ELISA, preferably under conditions essentially as described in the first paragraph of Example 4 herein.\n\n[0089] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is at most 100 nM, preferably at most 10 nM, more preferably at most 6 nM and most preferably at most 5 nM, wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11.\n\n[0090] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM, wherein further preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11.\n\n[0091] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 0.01 pM to 1000 nM, preferably 0.1 pM to 100 nM, more preferably 0.1 pM to 10 nM, still more preferably 0.1 pM to 1 nM, still more preferably 0.1 pM to 100 pM, still more preferably 0.1 pM to 50 pM, still more preferably 0.1 pM to 20 pM, still more preferably 0.1 pM to 15 pM, still more preferably 1 pM to 15 pM, and most preferably 1 pM to 10 pM, wherein preferably said influenza M2e antigen is an RNAse conjugate of the extracellular domain of influenza A M2 protein, most preferably in solution, wherein further preferably said influenza M2e antigen comprises the peptide of any one of SEQ ID NOs 48 to 83 and 90 to 92, more preferably of any one of SEQ ID NOs 48 to 50, and most preferably of SEQ ID NO:48, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11.\n\n[0094] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 1 1, and wherein further preferably said LC CDRl consists of the peptide of any one of SEQ ID NOs 1, 4 and 6, said LC CDR2 consists of the peptide of SEQ ID NO:7, said LC CDR3 consists of the peptide of SEQ ID NO:8, said HC CDRl consists of the peptide of SEQ ID NO: 12, said HC CDR2 consists of the peptide of SEQ ID NO: 13, and said HC CDR3 consists of the peptide of SEQ ID NO: 15.\n\n[0095] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11, and wherein further preferably said LC CDRl consists of the peptide of SEQ ID NO:1, said LC CDR2 consists of the peptide of SEQ ID NO:7, said LC CDR3 consists of the peptide of SEQ ID NO:8, said HC CDRl consists of the peptide of SEQ ID NO: 12, said HC CDR2 consists of the peptide of SEQ ID NO:13, and said HC CDR3 consists of the peptide of SEQ ID NO:15.\n\n[0096] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11, and wherein position 5 to 113 of said LCVR consists of the peptide of any one of SEQ ID NOs 20, 21 and 22.\n\n[0097] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11, and wherein position 7 to 121 of said HCVR consists of the peptide of SEQ ID NO:23.\n\n[0098] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5 nM, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11, and wherein position 5 to 113 of said LCVR consists of the peptide of any one of SEQ ID NOs 20, 21 and 22, and wherein position 7 to 121 of said HCVR consists of the peptide of SEQ ID NO:23.\n\n[0099] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11, and wherein position 5 to 113 of said LCVR consists of the peptide of SEQ ID NO:20, and wherein position 7 to 121 of said HCVR consists of the peptide of SEQ ID NO :23.\n\n[00100] In a further preferred embodiment said monoclonal antibody is specifically binding influenza M2e antigen, wherein the dissociation constant (Kd) of said monoclonal antibody and said influenza M2e antigen is 1 to 100 nM, preferably 1 to 10 nM, more preferably 1 to 6 nM, still more preferably 3 to 6 nM, and most preferably 4 to 5, and wherein preferably said influenza M2e antigen is SEQ ID NO:48, most preferably in solution, and wherein still further preferably said Kd is determined by Friguet-ELISA, most preferably under conditions essentially as described in Example 11 , and wherein said monoclonal antibody is a human IgG, preferably a human IgGl, wherein preferably said human IgGl comprises at least one, preferably exactly two, kappa LC(s), wherein said kappa LC(s) comprise(s) or more preferably consist(s) of a peptide of any one of SEQ ID NOs 26 to 28, preferably SEQ ID NO:20, and wherein said monoclonal antibody comprises at least one, preferably exactly two, gamma 1 HC(s), wherein said gamma 1 HC(s) comprise(s) or more preferably consist(s) of the of SEQ ID NO:29."}
{"raw_mentions": "In total, 53 ELISA-positive clones encoding M2e-specific scFv antibodies, each binding with an EC50 in the range of 2 to 10 ng/ml (approximately 18 to 90 pM), were sequenced as described (see WO 2008/055795 Al)."}
{"final_json": [{"molecule_name": "M2e-specific scFv antibodies", "protein_target_name": "M2e", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "2 to 10", "unit": "ng/ml"}, {"molecule_name": "M2e-specific scFv antibodies", "protein_target_name": "M2e", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "18 to 90", "unit": "pM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe antibodies scFv-D005-msFc\u03b32c, scFv-E040-msFc\u03b32c and scFv-F052-msFc\u03b32c were found to bind native, cell surface-expressed M2-PR with a high affinity, with an EC50 of 0.68, 0.73 and 0.46 nM, respectively.\nTable 6. Inhibition of scFv-msFc\u03b32c binding to immobilized M2e by soluble M2 peptides. EC50 values (\u03bcM) of inhibition of binding are shown."}
{"final_json": [{"molecule_name": "scFv-D005-msFc\u03b32c", "protein_target_name": "M2-PR", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "0.68", "unit": "nM"}, {"molecule_name": "scFv-E040-msFc\u03b32c", "protein_target_name": "M2-PR", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "0.73", "unit": "nM"}, {"molecule_name": "scFv-F052-msFc\u03b32c", "protein_target_name": "M2-PR", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "0.46", "unit": "nM"}, {"molecule_name": "scFv-msFc\u03b32c", "protein_target_name": "M2e", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": null, "unit": "\u03bcM"}]}
